로딩 중…
지수 로딩 중…
4D Molecular Therapeutics, Inc.
FDMT· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$10.09-0.88%
2026-08-03
Financials
Valuation Metrics
4D Molecular Therapeutics, Inc.'s Market Cap is $527M. At end of 2025 it was $434M. Ranked #2767 of 3,111 in US market (top 89%), #1198 of 1,445 on NASDAQ (top 83%), #219 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 81%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $527M | US#2,767/3,111 Sec#219/269 |
| Revenue | $88M | US#2,811/3,111 Sec#131/269 |
| Net Income | $-161M | US—/3,111 Sec—/269 |
| Total Assets | $513M | US#2,739/3,111 Sec#154/269 |
| Net Assets | $452M | US#2,328/3,111 Sec#124/269 |
| Value | ||
| P/B | 1.17x | US#525/3,111 Sec#27/269 |
| P/S | 5.98x | US#2,403/3,111 Sec#95/269 |
| FCF Yield | -24.66% | US—/3,111 Sec—/269 |
| Profitability | ||
| ROE | -35.61% | US#2,663/3,111 Sec#141/269 |
| ROA | -31.37% | US#2,888/3,111 Sec#166/269 |
| Op. Margin | -203.47% | US#2,866/3,111 Sec#138/269 |
| Revenue Growth | 21664.29% | US#6/3,111 Sec#1/269 |
| Financial Health | ||
| Debt Ratio | 13.52% | US#155/3,111 Sec#66/269 |
| Total Debt | $21M | US#2,724/3,111 Sec#181/269 |
| FCF | $-130M | US#2,651/3,111 Sec#174/269 |
| Cash | $72M | US#2,402/3,111 Sec#201/269 |
| Current Ratio | 9.34x | US#263/3,111 Sec#87/269 |
| Performance | ||
| 1Y Return | 57.17% | US#200/3,111 Sec#61/269 |
| 1M Return | -22.38% | US#2,829/3,111 Sec#236/269 |
| From 52W High | -27.93% | US#2,000/3,111 Sec#147/269 |
| 1Y MDD | -41.40% | US#2,014/3,111 Sec#149/269 |
| Trading | ||
| Volume | 447,197 shares | US#1,746/3,111 Sec#166/269 |
| Trading Value | $4M | US#2,453/3,111 Sec#202/269 |
| Per Share | ||
| EPS | $-2.42 | US—/3,111 Sec—/269 |
| BPS | $8.73 | US#1,879/3,111 Sec#74/269 |